Increased plasma phosphatidylcholine/lysophosphatidylcholine ratios in patients with Parkinson's disease
Authorized Users Only
2020
Authors
Miletić Vukajlović, Jadranka
Drakulić, Dunja R.

Pejić, Snežana

Ilić, Tihomir V.

Stefanović, Aleksandra
Petković, Marijana

Schiller, Jürgen
Article (Published version)

© 2019 John Wiley & Sons, Ltd
Metadata
Show full item recordAbstract
Rationale: Changes in lipid composition might be associated with the onset and progression of various neurodegenerative diseases. Herein, we investigated the changes in the plasma phosphatidylcholine (PC)/lysophosphatidylcholine (LPC) ratios in patients with Parkinson's disease (PD) in comparison with healthy subjects and their correlation with clinico-pathological features. Methods: The study included 10 controls and 25 patients with PD. All patients were assigned to groups based on clinico-pathological characteristics (gender, age at examination, duration of disease and Hoehn and Yahr (H&Y) stage). The analysis of the PC/LPC intensity ratios in plasma lipid extracts was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Results: PD patients exhibited an increased PC/LPC intensity ratio in comparison with the control group of healthy subjects. Furthermore, the investigated ratio was shown to be correlated with clinico-pathological parameters,... in particular with H&Y stage and disease duration. The PC/LPC intensity ratio in plasma samples of PD patients was found to be elevated in all examined H&Y stages and throughout the disease duration. Conclusions: To our knowledge, this is the first study examining the PC/LPC ratios in plasma of patients with PD and illustrating their correlation with clinico-pathological features. Although the presented results may be considered as preliminary due to the limited number of participants, the observed alterations of PC/LPC ratios in plasma might be a first step in the characterization of plasma lipid changes in PD patients and an indicator of lipid reconfiguration. © 2019 John Wiley & Sons, Ltd.
Source:
Rapid Communications in Mass Spectrometry, 2020, 34, 4Funding / projects:
- German Research Foundation (DFG) [SFB 1052/Z3]
- German Research Foundation (DFG) [476/12-2]
- Cellular and molecular basis of neuroinflamation: potential targets for translational medicine and therapy (RS-41014)
- Basic and Clinical Pharmacological research of mechanisms of action and drug interactions in nervous and cardiovascular system (RS-175023)
DOI: 10.1002/rcm.8595
ISSN: 0951-4198
PubMed: 31519070
WoS: 000508347200007
Scopus: 2-s2.0-85078298349
Collections
Institution/Community
VinčaTY - JOUR AU - Miletić Vukajlović, Jadranka AU - Drakulić, Dunja R. AU - Pejić, Snežana AU - Ilić, Tihomir V. AU - Stefanović, Aleksandra AU - Petković, Marijana AU - Schiller, Jürgen PY - 2020 UR - https://vinar.vin.bg.ac.rs/handle/123456789/8476 AB - Rationale: Changes in lipid composition might be associated with the onset and progression of various neurodegenerative diseases. Herein, we investigated the changes in the plasma phosphatidylcholine (PC)/lysophosphatidylcholine (LPC) ratios in patients with Parkinson's disease (PD) in comparison with healthy subjects and their correlation with clinico-pathological features. Methods: The study included 10 controls and 25 patients with PD. All patients were assigned to groups based on clinico-pathological characteristics (gender, age at examination, duration of disease and Hoehn and Yahr (H&Y) stage). The analysis of the PC/LPC intensity ratios in plasma lipid extracts was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Results: PD patients exhibited an increased PC/LPC intensity ratio in comparison with the control group of healthy subjects. Furthermore, the investigated ratio was shown to be correlated with clinico-pathological parameters, in particular with H&Y stage and disease duration. The PC/LPC intensity ratio in plasma samples of PD patients was found to be elevated in all examined H&Y stages and throughout the disease duration. Conclusions: To our knowledge, this is the first study examining the PC/LPC ratios in plasma of patients with PD and illustrating their correlation with clinico-pathological features. Although the presented results may be considered as preliminary due to the limited number of participants, the observed alterations of PC/LPC ratios in plasma might be a first step in the characterization of plasma lipid changes in PD patients and an indicator of lipid reconfiguration. © 2019 John Wiley & Sons, Ltd. T2 - Rapid Communications in Mass Spectrometry T1 - Increased plasma phosphatidylcholine/lysophosphatidylcholine ratios in patients with Parkinson's disease VL - 34 IS - 4 DO - 10.1002/rcm.8595 ER -
@article{ author = "Miletić Vukajlović, Jadranka and Drakulić, Dunja R. and Pejić, Snežana and Ilić, Tihomir V. and Stefanović, Aleksandra and Petković, Marijana and Schiller, Jürgen", year = "2020", abstract = "Rationale: Changes in lipid composition might be associated with the onset and progression of various neurodegenerative diseases. Herein, we investigated the changes in the plasma phosphatidylcholine (PC)/lysophosphatidylcholine (LPC) ratios in patients with Parkinson's disease (PD) in comparison with healthy subjects and their correlation with clinico-pathological features. Methods: The study included 10 controls and 25 patients with PD. All patients were assigned to groups based on clinico-pathological characteristics (gender, age at examination, duration of disease and Hoehn and Yahr (H&Y) stage). The analysis of the PC/LPC intensity ratios in plasma lipid extracts was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Results: PD patients exhibited an increased PC/LPC intensity ratio in comparison with the control group of healthy subjects. Furthermore, the investigated ratio was shown to be correlated with clinico-pathological parameters, in particular with H&Y stage and disease duration. The PC/LPC intensity ratio in plasma samples of PD patients was found to be elevated in all examined H&Y stages and throughout the disease duration. Conclusions: To our knowledge, this is the first study examining the PC/LPC ratios in plasma of patients with PD and illustrating their correlation with clinico-pathological features. Although the presented results may be considered as preliminary due to the limited number of participants, the observed alterations of PC/LPC ratios in plasma might be a first step in the characterization of plasma lipid changes in PD patients and an indicator of lipid reconfiguration. © 2019 John Wiley & Sons, Ltd.", journal = "Rapid Communications in Mass Spectrometry", title = "Increased plasma phosphatidylcholine/lysophosphatidylcholine ratios in patients with Parkinson's disease", volume = "34", number = "4", doi = "10.1002/rcm.8595" }
Miletić Vukajlović, J., Drakulić, D. R., Pejić, S., Ilić, T. V., Stefanović, A., Petković, M.,& Schiller, J.. (2020). Increased plasma phosphatidylcholine/lysophosphatidylcholine ratios in patients with Parkinson's disease. in Rapid Communications in Mass Spectrometry, 34(4). https://doi.org/10.1002/rcm.8595
Miletić Vukajlović J, Drakulić DR, Pejić S, Ilić TV, Stefanović A, Petković M, Schiller J. Increased plasma phosphatidylcholine/lysophosphatidylcholine ratios in patients with Parkinson's disease. in Rapid Communications in Mass Spectrometry. 2020;34(4). doi:10.1002/rcm.8595 .
Miletić Vukajlović, Jadranka, Drakulić, Dunja R., Pejić, Snežana, Ilić, Tihomir V., Stefanović, Aleksandra, Petković, Marijana, Schiller, Jürgen, "Increased plasma phosphatidylcholine/lysophosphatidylcholine ratios in patients with Parkinson's disease" in Rapid Communications in Mass Spectrometry, 34, no. 4 (2020), https://doi.org/10.1002/rcm.8595 . .